Specialty Research: Stellar Gene Therapy And Gene Editing Innovators – Seeking Alpha
|
Specialty Research: Stellar Gene Therapy And Gene Editing Innovators
Seeking Alpha Despite over five decades of failure, Spark Therapeutics (NASDAQ:ONCE) earned the unprecedented FDA approval of voretigene neparvovec-rzyl (Luxturna) – a one-time gene therapy for patients afflicted with biallelic RPE65 mutation-associated retinal … |
